Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Lamotrigine vs BANZEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.
BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.
Bipolar I disorder (maintenance treatment),Partial-onset seizures (adjunctive therapy),Primary generalized tonic-clonic seizures (adjunctive therapy),Lennox-Gastaut syndrome (seizures),Off-label: neuropathic pain, trigeminal neuralgia, schizophrenia augmentation
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 1 year of age and older (FDA-approved),Off-label: Adjunctive therapy for partial-onset seizures, generalized tonic-clonic seizures, and other refractory epilepsies
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.
400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.
25.4 h (range 24-31 h, prolonged to 59 h with valproate)
Terminal elimination half-life is approximately 6-10 hours in adults; in pediatric patients, it is shorter (~3-6 hours). Steady-state is reached within 1-2 days.
Primarily metabolized by UDP-glucuronosyltransferases (UGT1A4, UGT2B7). Minimal involvement of CYP450 enzymes. Autoinduction of its own metabolism with chronic use.
Primarily hydrolyzed by carboxylesterases in the liver to inactive metabolites (CGP 47292). Minor metabolism via CYP450 enzymes (CYP2E1, CYP3A4, CYP1A2, CYP2B6, CYP2C9, CYP2C19) but not significantly.
Renal (94% as metabolites, 10% unchanged; 2% fecal)
Primarily renal: approximately 66% of the dose excreted in urine (30% as unchanged rufinamide, 70% as inactive metabolites). Fecal excretion: ~4%. No significant biliary excretion.
55% (binds to albumin)
Approximately 34% bound to plasma proteins, primarily albumin.
1.2 L/kg (distribution into tissues, including brain)
Apparent volume of distribution is approximately 0.7-1.0 L/kg, indicating distribution primarily into total body water.
Oral: 98% (immediate-release); ~90% (extended-release)
Absolute oral bioavailability is approximately 85% (high). Food increases Cmax and AUC by about 30-40%, but this is not considered clinically significant for dosing.
e GFR <30 m L/min/1.73 m²: use with caution; no specific dose adjustment recommended. e GFR <10 m L/min: reduce dose by 50% and monitor.
Cr Cl < 30 m L/min: not recommended. Cr Cl 30-50 m L/min: maximum dose 400 mg twice daily. Cr Cl > 50 m L/min: no adjustment.
Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: reduce dose by 75%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: start 200 mg twice daily, maximum 400 mg twice daily. Child-Pugh Class C: not recommended.
2-12 years: 0.15 mg/kg/day once daily for 2 weeks, then 0.3 mg/kg/day once daily for 2 weeks, then increase by 0.3 mg/kg/day every 1-2 weeks. Maintenance: 1-5 mg/kg/day divided twice daily. Maximum: 400 mg/day.
Age ≥4 years: based on body weight. Starting dose: 10 mg/kg/day divided twice daily, titrate weekly by increments of 10 mg/kg/day to target maintenance 40 mg/kg/day (max 3200 mg/day). Max single dose: 1600 mg twice daily.
Lower initial doses (25 mg every other day) and slower titration due to increased sensitivity and slower clearance; monitor for adverse effects.
No specific dose adjustment, but consider age-related renal impairment; monitor Cr Cl.
Life-threatening rashes, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), especially in pediatric patients and with rapid dose escalation.
None
Risk of serious rash (SJS/TEN); hemophagocytic lymphohistiocytosis (HLH); aseptic meningitis; multiorgan hypersensitivity reactions; suicidal thoughts and behavior; blood dyscrasias; cardiac conduction abnormalities; increased seizure frequency with abrupt withdrawal.
May shorten QT interval; use caution with other drugs that shorten QT interval. Increased risk of suicidal thoughts/behavior. Monitor for hypersensitivity reactions (including DRESS). Central nervous system depression (dizziness, somnolence, ataxia). May decrease efficacy of hormonal contraceptives. Withdrawal seizures if abruptly discontinued. Dose adjustment needed in severe hepatic impairment.
Hypersensitivity to lamotrigine or any component of the formulation.
Familial short QT syndrome (due to QT interval shortening). Hypersensitivity to rufinamide or any of its components.
No significant food interactions. Grapefruit has no effect. Alcohol may increase CNS depression and dizziness; limit or avoid.
BANZEL should be taken with food to increase bioavailability (Cmax increases by approximately 40% and AUC by 50% compared to fasting). Avoid grapefruit juice as it may alter drug metabolism. No other food interactions are documented.
First trimester exposure increases risk of oral clefts (cleft lip/palate) (absolute risk ~0.3-0.9% vs 0.2% background). Second/third trimester: risk of neural tube defects, cardiac malformations, and developmental delay. Higher doses (>300 mg/day) and polytherapy increase risk. Folate supplementation recommended.
First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of intrauterine growth restriction, neurodevelopmental delay, and hemorrhagic disease of the newborn due to vitamin K deficiency.
Lamotrigine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6. Infant serum concentrations can reach 25-50% of maternal levels. Risk of rash, apnea, drowsiness; benefits likely outweigh risks in most cases. Monitor infant for adverse effects.
Rufinamide is excreted in human milk. The milk-to-plasma ratio is approximately 0.3. Breastfeeding is not recommended due to potential adverse effects in the infant, including somnolence, poor feeding, and weight loss.
Clearance increases by 50-330% during pregnancy, particularly in second and third trimesters. Dose may need to be increased (up to 2-3 times pre-pregnancy dose) to maintain therapeutic levels. Postpartum clearance returns to baseline within 1-2 weeks, requiring dose reduction to avoid toxicity.
Pregnancy may reduce serum concentrations due to increased clearance and volume of distribution. Monitor trough levels and adjust dose to maintain therapeutic efficacy. Postpartum, monitor for toxicity as levels may rise.
Titrate slowly to minimize risk of Stevens-Johnson syndrome; start 25 mg/day for weeks 1–2, then 50 mg/day for weeks 3–4. Drug interactions: valproate doubles lamotrigine half-life and increases SJS risk; estrogen-containing contraceptives reduce lamotrigine levels by ~50%. Therapeutic serum level: 2.5–15 mcg/m L. Monitor for rash, especially in first 8 weeks.
BANZEL (rufinamide) is an antiepileptic drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients ≥1 year. Titrate slowly over 2-3 weeks to reduce risk of adverse effects. Monitor for shortened QT interval; contraindicated in familial short QT syndrome. Dose adjustments needed in severe hepatic impairment. May decrease efficacy of oral contraceptives containing ethinyl estradiol. Administer with food to enhance absorption.
Report any rash, hives, or blisters immediately; may be sign of serious skin reaction.,Do not stop taking abruptly; taper under doctor's guidance to avoid rebound seizures.,Take missed dose as soon as remembered unless close to next dose; do not double.,Oral contraceptives and hormone therapy can reduce lamotrigine effectiveness; discuss with doctor.,Avoid driving or operating machinery until effects are known; may cause dizziness or blurred vision.
Take BANZEL exactly as prescribed with food to improve absorption.,Do not stop taking BANZEL suddenly; taper under medical supervision to avoid withdrawal seizures.,Inform your doctor if you have a heart condition, especially short QT syndrome.,Use effective contraception if applicable; BANZEL may reduce efficacy of oral contraceptives.,Monitor for dizziness, drowsiness, or coordination problems; avoid driving until you know how BANZEL affects you.,Report any unusual tiredness, fatigue, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.
"Telithromycin is a potent inhibitor of CYP3A4, while lamotrigine is primarily metabolized by UGT1A4 and not significantly by CYP3A4. However, telithromycin may also inhibit UGT1A4, leading to reduced lamotrigine clearance and increased risk of lamotrigine toxicity, including severe rash (Stevens-Johnson syndrome) and central nervous system depression. Concurrent use may require lamotrigine dose adjustment to avoid adverse effects."
"Concomitant use of Lormetazepam, a benzodiazepine that enhances GABAergic inhibition, and Lamotrigine, a sodium channel blocker and glutamate release inhibitor, may result in additive central nervous system depression and an increased risk of sedation, dizziness, and psychomotor impairment. The interaction is primarily pharmacodynamic, as both drugs have CNS depressant effects, potentially leading to excessive drowsiness and impaired coordination. Clinical outcomes may include increased fall risk, cognitive dysfunction, and compromised ability to perform tasks requiring alertness."
"Concurrent use of paliperidone and lamotrigine may increase the risk of central nervous system depression and synergistic adverse effects, including sedation, dizziness, and impaired cognitive function. Paliperidone, an atypical antipsychotic, and lamotrigine, an anticonvulsant, both modulate neurotransmitter systems, potentially leading to additive pharmacodynamic effects. Clinically, this can result in increased sedation, confusion, and an elevated risk of falls or accidents, particularly in elderly patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Lamotrigine vs BANZEL, answered by our medical review team.
Lamotrigine is a Anticonvulsant that works by Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.. BANZEL is a Anticonvulsant that works by BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Lamotrigine and BANZEL depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Lamotrigine is: Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.. The standard adult dose of BANZEL is: 400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Lamotrigine and BANZEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Lamotrigine is classified as Category A/B. First trimester exposure increases risk of oral clefts (cleft lip/palate) (absolute risk ~0.3-0.9% vs 0.2% background). Second/third trimester: risk of neural tube defects, cardiac. BANZEL is classified as Category C. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.